1 / 4

Serum Institute’s Vaccine Demonstrates Significant Efficacy Against Severe Rotavirus Gastroenteritis.

NewsVoir is one of the leading names who offer comprehensive press release distribution India and news distribution services with a large network for maximum reach. To know more, reach us at - http://www.newsvoir.com/press-release-distribution.html

newsonline
Download Presentation

Serum Institute’s Vaccine Demonstrates Significant Efficacy Against Severe Rotavirus Gastroenteritis.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Serum Institute’s Vaccine Demonstrates Significant Efficacy Against Severe Rotavirus Gastroenteritis.

  2. Indian Government orders the vaccine for use in Universal Immunization Programme. Pune, Maharashtra, India Results from a Phase 3 efficacy study in India of the Serum Institute of India Pvt. Ltd.’s rotavirus vaccine BRV-PV (known as ROTASIIL®) were published in the journal Vaccine. The study showed the vaccine to be safe, well tolerated, and to provide significant efficacy against severe rotavirus gastroenteritis. In 2013, an estimated 47,100 rotavirus deaths occurred in India, 22 percent of all rotavirus deaths that occurred globally.

  3. India bears a high diarrheal disease burden and rotavirus vaccines will check death and illness among children.

  4. ROTASIILreduced severe rotavirus diarrhea by more than a third – 39.5 percent over two years. Significantly, the vaccine efficacy was nearly 55 percent against the most severe and potentially life-threatening cases of rotavirus diarrhea, which represent the highest risk of dehydration, hospitalizations, and deaths. The results demonstrated by ROTASIIL in India appear generally comparable to the performance of RotaTeq® and Rotarix® in Bangladesh and in some African countries. Referral link: http://www.newsvoir.com/

More Related